GEN Exclusives

More »

GEN News Highlights

More »
Jan 22, 2009

Biovitrum to Divest R&D Segment Cambridge Biotechnology

  • Biovitrum decided to spin out its small molecule R&D subsidiary, Cambridge Biotechnology (CBT), and a range of primary care projects. Biovitrum will focus on specialist pharmaceuticals and protein therapeutics.

    CBT’s pipeline includes a Phase II neuropathic pain project and obesity candidates in Phase II and Phase I trials. The company also has a leptin mimetic preclinical drug in obesity as well as a pain and inflammation preclinical program and four discovery programs in pain and inflammation.

    Biovitrum, on the other hand, retains hemophilia and fat malabsorption clinical programs. Both are in mid-stage development. The firm reported net revenues from January to September 2008 of SEK 826.3 million, or $99.78 million. Its portfolio has therapies for oncology, rheumatoid arthritis, hemophilia, anticoagulation, and calcium hemostasis, including three biologics that it recently bought from Amgen for $150 million.



Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »